🔎 Trials Near Me

Home › Non-Small Cell Lung Cancer › North Carolina

Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa North Carolina

79 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa North Carolina.

Mga Lungsod sa North Carolina

Opisyal na teksto ng pag-aaral (English)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06568939

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07388524

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Wake Forest University at Clemmons, Clemmons
  • at 8 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04267848

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Carolina Cancer Research Center, Wilson
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06270706

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Duke University, Durham
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04585750

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
  • Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06623422

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #12, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • Charles George VA Medical Center ( Site 3233), Asheville
  • UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill
  • WakeMed Raleigh Campus ( Site 3214), Raleigh
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07513376

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  • WakeMed Raleigh Campus ( Site 0144), Raleigh
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Duke Cancer Center Cary, Cary
  • Durham VA Medical Center, Durham
  • Duke University Medical Center, Durham
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Novant Health Pharmacy Oncology Specialists, Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • Novant Health Pharmacy Oncology Specialists, Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • Carolinas Medical Center, Charlotte
  • Duke Cancer Center, Durham
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06765109

A Study of PHN-012 in Patients With Advanced Solid Tumors

  • PHN-012-001 Site, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07127874

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06881784

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • Levine Cancer Institute, Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04253964

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Messino Cancer Centers Asheville, Asheville
  • Duke University Medical Center, Durham
  • FirstHealth Cancer Center, Pinehurst
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05920356

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
  • FirstHealth Moore Regional Hospital, Pinehurst
  • Carolina Cancer Research Center, Wilson
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07222566

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • FirstHealth of the Carolinas, Pinehurst
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667908

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Atrium Health, Charlotte
  • Regional Medical Oncology Center, Wilson
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667076

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Brody School of Medicine at East Carolina University, Greenville
  • ECU Health Medical Center, Greenville
  • Carolina Cancer Research Center, Wilson
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • WakeMed Raleigh Campus, Raleigh
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06890598

Pan-tumor MRD Study

  • Carolina Oncology Specialists, Charlotte
  • Southeastern Medical Oncology Center (SMOC), Goldsboro
  • Regional Medical Oncology Center, Wilson
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Greenville
  • Research Site, Salisbury
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06357533

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

  • Atrium Health Levine Cancer, Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05696782

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06712316

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • Duke Cancer Center Durham, Durham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07488676

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  • FirstHealth of the Carolinas, Inc., Pinehurst
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06745882

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Carolina Biooncology Institute, Huntersville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Chapel Hill
  • Clinical Study Site, Durham
  • Clinical Study Site, Pinehurst
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  • Levine Cancer Institute, Charlotte
  • Durham VA Health Care System, Durham
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Duke University School of Medicine, Durham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Duke University Medical Center, Durham
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04613596

Effects of Infusion Timing on Treatment Response in Solid Tumors

  • University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07630168

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
  • Carolina Cancer Research Center, Wilson
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06899126

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.